Exenatide-PD3 is a clinical research trial for Parkinson\u2019s disease patients. It is a randomised, double-blind, placebo-controlled, parallel group phase 3 trial that will investigate the potential disease-modifying effects of Exenatide over two years.
Parkinson’s disease is the second most common neurodegenerative disease, and its prevalence is increasing. Currently, treatments for Parkinson’s can only help with the symptoms but they do not have an impact on the progressive nature of the disease. Exenatide is a licensed treatment for patients with type 2 diabetes and has been the subject of multiple phase 3 trials in patients with type 2 diabetes. Laboratory work has shown that Exenatide has beneficial effects on neurons in vitro and could have potential use as a neurodegenerative disease-modifying agent.
The primary objective of the trial is to compare the effectiveness of exenatide versus placebo over the course of two years. The study will look at clinical features of Parkinson’s Disease such as motor function, cognitive ability, quality of life, and side effects. If the trial is successful, exenatide could become an important new treatment for Parkinson’s disease, potentially slowing down the progression of the disease and improving patients’ quality of life.<\/p>\n\n\n